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Abstract
Aims: To compare interferon monotherapy with its combinationwith lamivudine
for hepatitis B e antigen (HBeAg)-positive hepatitis B treatment. Methods: Two
independent researchers identiﬁed pertinent randomized controlled trials. The
trials were evaluated for methodological quality and heterogeneity. Rates of
sustained virological and biochemical responses, and HBeAg clearance and
seroconversion were used as primary efﬁcacy measures. Quantitative meta-
analyses were conducted to assess differences between groups for conventional
and pegylated interferon, and overall. Results: Greater sustained virological,
biochemical and seroconversion rates were observed with addition of lamivudine
to conventional [odds ratio (OR)=3.1, 95% conﬁdence intervals (CI) (1.7–5.5),
Po0.0001, OR=1.8, 95% CI (1.2–2.7), P=0.007 and OR=1.8, 95% CI (1.1–2.8),
P=0.01 respectively], although not pegylated [OR=1.1, 95% CI (0.5–2.3), P=0.8,
OR=1.0, 95% CI (0.7–1.3), P=0.94, and OR=0.9, 95% CI (0.6–1.2), P=0.34
respectively] interferon-a, with no signiﬁcant affect on HBeAg clearance rates
[OR=1.6, 95% CI (0.9–2.7), P=0.09, and OR=0.8, 95% CI (0.6–1.1), P=0.26
respectively]. Excluding virological response (Po0.001), pegylated interferon
monotherapy and conventional interferon and lamivudine combination therapy
were similarly efﬁcacious (P40.05), with the former studied in harder to treat
patients, as evidenced by the superior virological response observed with conven-
tional as compared with pegylated interferon monotherapy (Po0.0001). Con-
clusion: In comparable populations, pegylated interferon monotherapy is likely to
be equally or more efﬁcacious than conventional interferon and lamivudine
combination therapy, thus constituting the treatment of choice, with no added
beneﬁt with lamivudine addition. However, when conventional interferon is used,
its combination with lamivudine should be considered.
Chronic hepatitis B is a common medical condition,
affecting more than 400 million individuals world-
wide, leading to hepatic inﬂammation and injury
(1–4). This viral-triggered, immune-mediated condi-
tion predisposes those affected to cirrhosis and hepa-
tocellular carcinoma, thus necessitating treatment
(1–3). The treatment consists of individualized,
single-agent therapy with interferon-a or nucleoside
analogues. Unfortunately, this treatment fails to yield
long-lasting outcomes in majority of the treated
population, prompting the notion of their use in
combination to enhance the therapeuticefﬁcacy (4–8).
The notion of combination therapy for chronic
hepatitis B treatment has been previously examined,
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aim to elucidate this topic comparing interferon
monotherapy to its combination with the best-studied
antiviral agent for that purpose, lamivudine. Further-
more, the focus of our analysis is hepatitis B e antigen
(HBeAg)-positive patients, a subset of the patient
population in which disease activity, risk of complica-
tions and the subsequent need of efﬁcacious therapy
are more pronounced.
Methods
Literature search and study design
Two independent researchers conducted the literature
search, study selection and data extraction, with any
disagreements resolved by consensus among them.
The researchers conducted a systemic literature
search using the electronic databases MEDLINE (1966
to January 2006), EMBASE (1980 to June 2006), OVID
(1966 to January, week 3, 2006) and the Cochrane
library clinical trials registry (issue 1, 2007). The
following keywords were used: ‘Hepatitis B’, ‘Interfer-
on’, ‘Lamivudine’ and ‘combination therapy’. In addi-
tion, a manual search using citations in previous
publications was preformed. The following inclusion
criteria were used: (i) study design: randomized con-
trolled trials; (ii) study population: HBeAg-positive
patients; (iii) intervention: interferon vs. interferon
and lamivudine therapy. Our search was not restricted
by language. The following exclusion criteria were
used: (i) examining the nonadult population; (ii) not
reporting any of the primary efﬁcacy measures as
deﬁned by the authors. When several publications
pertaining to a single study were identiﬁed, the most
recent and complete publication was used.
The included studies were divided into two groups
according to their use of conventional (CON) or
pegylated (PEG) interferon-a, with patients within
each group given interferon monotherapy, or interfer-
on and lamivudine combination therapy. Data were
extracted for study methodology and for the deﬁned
efﬁcacy measures. Only data pertaining to the regi-
mens in question were extracted, while data concern-
ing other regimens were reviewed, and if found to be
of signiﬁcance to our study, were noted and discussed.
Separate meta-analyses examining the deﬁned efﬁcacy
measures were preformed. In addition, we compared
the rates of sustained responses across groups aiming
at the identiﬁcation of a preferable regimen. Intention
to treat analysis was used throughout this study,
excluding histological response analysis, because of its
low outcomes reporting rates.
Efﬁcacy measures and deﬁnitions
End-of-follow-up (sustained) virological and biochem-
ical response rates, and sustained HBeAg clearance and
seroconversion rates were used as primary efﬁcacy
measures. Histological response, emergence of YMDD
mutations, liver-related and all-cause mortality, and
treatment safety were used as secondary efﬁcacy mea-
sures. Virological response was deﬁned as attainment of
undetectable (or below 400copies/mL) levels of hepati-
tis B virus DNA, as determined by polymerase chain
reaction, which was previously found to be the most
accurate measure of virological response monitoring
(2). Biochemical response was deﬁned as normalization
of alanine aminotransferase levels, HBeAg clearance as
HBeAg disappearance and seroconversion as HBeAg
antibodies appearance. Histological response was de-
ﬁned as a two-point reduction or increase in the
histologic activity index score, signifying histological
improvement and worsening respectively. Treatment
safety was assessed using the occurrence rate of adverse
effects necessitating treatment discontinuation.
Study quality and homogeneity
The included studies methodological quality was as-
sessed using the Jadad quality scale (15), an established
composite score evaluating randomization, conceal-
ment andreporting of patientwithdrawal and dropout
rates, with scores Z3 signifying high-quality studies.
Heterogeneity was assessed for each analysis.
Statistical analysis
Quantitative meta-analyses were performed to assess
differences between monotherapy and combination
groups. Statistical analysis was performed and the
Forest plots were generated using the COMPREHENSIVE
META ANALYSIS
s software application, Version 2.0 (Bio-
stat, Englewood, NJ, USA). The odds ratios (OR) were
calculated along with their, respective, 95% confidence
intervals (CI) and presented for each individual study
as well as interferon type and across all studies.
Subgroup analyses were presented using OR and their
corresponding 95% CI. Heterogeneity was assessed for
each of the meta-analyses by means of Q-statistics and
their corresponding P-values.
Results
Study selection and characteristics
The literature search yielded 13 studies. Five studies
were excluded on account of the following: (i) exam-
ining the nonadult population (n=1); and (ii) not
examining or reporting the sustained response rates
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patients, were included. Six trials used conventional
interferon-a (n=503) (16–21) and two trials used
pegylated interferon-a (n=808) (22, 23). Two of the
CON group trials exclusively studied treatment-naı ¨ve
patients (16, 19), whereas the others studied a mixture
of treatment-naı ¨ve and previously treated patients (17,
18, 20–23). The majority of patients were treated for a
period of 1 year (n=6) (16–23), with some treated for
6 months (n=2) (17, 18). Sustained response rates
were obtained at 6 months following treatment com-
pletion in most studies (n=6) (17, 19–23), and at 40
or 54 weeks following treatment completion in some
(n=2) (16, 18). The studies were of heterogeneous
methodological quality (Jadad scores of 2–5). All
studies were published as full publications, with six
studies published in English (16–19, 22, 23) and twoin
Chinese (20, 21). One study used sequential therapy
(18), six used concurrent therapy (16, 17, 19,21–23)
and one used both (20) (see Tables 1 and 2).
Sustained virological response
Greater sustained virological response rates were ob-
served for patients given combination as compared
with monotherapy in the CON group [61.1 vs. 35.4%,
OR=11.7, 95% CI (7.8–17.6), Po0.0001], and over-
all [28.9 vs. 18.5%, OR=2.1, 95% CI (1.3–3.3),
P=0.002], although not in the PEG group [12.2 vs.
11.8%, OR=1.1, 95% CI (0.5–2.3), P=0.8]. Hetero-
geneity was assessed and not found to be a concern
(Q=3.5, P=0.06) (see Fig. 1).
Sustained biochemical response
Greater sustained biochemical response rates were
observed for patients given combination as compared
with monotherapy in the CON group [46.2 vs. 34.0%,
OR=1.8, 95% CI (1.2–2.7), P=0.007], although not
in the PEG group [37.9 vs. 38.1%, OR=1.0, 95% CI
(0.7–1.3), P=0.94], or overall [36.1 vs. 36.7%,
OR=1.2, 95% CI (0.9–1.5), P=0.15]. Heterogeneity
was assessed and not found to be a concern (Q=3.3,
P=0.07) (see Fig. 2).
Sustained hepatitis B e antigen clearance
No signiﬁcant differences in sustained HBeAg clear-
ance rates were observed between patients given com-
bination and monotherapy in the CON group [33.5 vs.
24.0%, OR=1.6, 95% CI (0.9–2.7), P=0.09], PEG
group [30.6 vs. 34.4%, OR=0.8, 95% CI (0.6–1.1),
P=0.26] and overall [31.5 vs. 31.9%, OR=1.0, 95%
CI (0.7–1.3),P=0.88].Heterogeneity was assessedand
not found to be a concern (Q=2.6,P=0.11)(see Fig.3).
Sustained seroconversion
Greater sustained seroconversion rates were observed
for patients given combination as compared with
monotherapy in the CON group [30.0 vs. 18.9%,
OR=1.8, 95% CI (1.1–2.8), P=0.01], although not
in the PEG group [27.9 vs. 31.0%, OR=0.9, 95% CI
(0.6–1.2), P=0.34], or overall [28.7 vs. 27.1%,
OR=1.1, 95% CI (0.8–1.4), P=0.59]. Heterogeneity
was assessed and not found to be a concern (Q=3.5,
P=0.06) (see Fig. 4).
Histological response
Greater histological improvement rates were observed
for patients given combination as compared with
monotherapy in the CON group [83.8 vs. 26.6%,
respectively, n=1, OR=14.3, 95% CI (3.3–61.3),
Po0.001], although not in the PEG group [48.1 vs.
53.4%, respectively, n=1, OR=0.8, 95% CI (0.4–1.7),
P=0.70], or overall [61.4 vs. 47.9%, respectively, n=2,
OR=1.7, 95% CI (0.9–3.3), P=0.11]. No signiﬁcant
differences in histological worsening rates were ob-
served between patients given combination and
Table 1. Characteristics of studies included in the meta-analysis
Study n
Study
design
Jadad
score
Therapy
period
Follow-up
period Therapy regimen
Conventional interferon-a
Ayaz (2006) 68 RCT 2 12m 6m INF-a-2a 9MU 3/w with or without LMV 100mg/day
Song (2004) 90 RCT 2 12m 6m INF-a 3MU 3/w with or without LMV 100mg/day
Deng (2003) 62 RCT 2 48w 24w INF-a-1b 5MU 3/w with or without LMV 100mg/day
Yalcin (2002) 49 RCT 2 52w 52w INF-a-2b 10MU 3/w with or without LMV 100mg/day
Cindoruk (2002) 100 RCT 2 6m 6m INF-a 9MU 3/w with or without LMV 100mg/day
Schalm (2000) 144 RCT, DB 4 24w 40w INF-a 10MU 3/w with or without LMV 100mg/day
Pegylated interferon-a
Lau (2005) 542 RCT, DB 5 48w 24w PegINF-a-2a 180mg 1/w with or without LMV 100mg/day
Janssen (2005) 266 RCT, DB 4 52w 26w PegINF-a-2b 100mg 1/w with or without LMV 100mg/day
DB, double blind; INF, conventional interferon; LMV, lamivudine; m, months; PegINF, pegylated interferon; RCT, randomized controlled; w, weeks.
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Study Inclusion criteria Exclusion criteria
Ayaz (2006) 1. HBsAg positive for 46m and anti-HBeAg and
HBsAg negative
2. Presence of HBV DNA
3. Evidence of inﬂammation on biopsy within 6m
of enrolment and ALT41.5NL
1. Previous treatment with INF, antiviral or immunosuppressive
agents
2. HIV, hepatitis C or D
3. Other aetiologies of liver disease, alcohol intake 440g/day,
decompensated liver disease or cancer
4. No informed consent
5. Pregnancy
6. Any contraindications for INF use
7. Leucocytes, neutrophil or platelet count of o2500, o1000
and o100000/mL, respectively, or haemoglobin o10g/dL
Song (2004) 1. 19–65 years old
2. HBsAg positive for 46m and HBeAg positive
3. HBV DNA4500000copies/mL
4. Evidence of inﬂammation by 2NL oALT o500
Not reported
Deng (2003) 1. 15–60 years old
2. HBeAg and HBV DNA positive for 46m
3. HBV DNA4103000copies/mL
4. Evidence of inﬂammation by ALT42NL
1. Immunosuppressive or antiviral therapy within 6m
2. Hepatitis of other aetiologies
3. Decompensated liver disease
4. Pregnancy or breast feeding
Yalcin (2002) 1. 16–80 years old
2. HBeAg and HBsAg positive
3. HBV DNA positive
4. Evidence of inﬂammation by histology and
1.5oALTo10NL, on three occasions within
6m
1. Previous INF therapy, antiviral or immunosuppressive therapy,
or contraindication for INF therapy
2. HIV, hepatitis C or D
3. Decompensated liver disease or carcinoma
4. Alcohol consumption 440g/day orother liverdisease causes
5. Pregnancy
6. Leucocytes o2500/mm
3, neutrophils o1000/mm
3,
platelets o100000/mm
3, or haemoglobin o10g/dL
7. Unable to obtain consent
Cindoruk (2002) 1. Adults
2. HBeAg positive
3. HBV DNA positive
4. Evidence of inﬂammation by histology and by
abnormal ALT levels for 46m
1. Previous INF therapy
2. HIV, hepatitis C or D
3. Decompensated liver disease
4. Diabetes, autoimmune, orother psychiatric or serious medical
illness
5. High alcohol intake or current drug abuse
6. Pregnancy
Schalm (2000) 1. 16–70 years old
2. HBsAg and HBeAg positive at screening and at
46 and 43m prior respectively
3. HBV DNA4500000copies/mL
4. Evidence of inﬂammation by histology or
persistently elevated ALT for 43m
1. Contraindication to or previous INF therapy, or antiviral
therapy within 6m
2. HIV, hepatitis C or D
3. Decompensated liver disease
4. Liver disease of other aetiology
Lau (2005) 1. Adults
2. HBsAg positive for 46m and HBeAg positive
3. HBV DNA4500000copies/mL
4. Evidence of inﬂammation on biopsy and
1oALTo10NL
1. Treatment within 6m
2. HIV, hepatitis C or D
3. Decompensated liver disease
4. Serious medical or psychiatric illness
5. Alcohol or drug use within 1y
4. Neutrophils o1500g/dL, platelets o90000/mm
3,o r
creatinine 41.5NL
Janssen (2005) 1. 416 years old
2. HBsAg positive for 46m and HBeAg positive
on two occasions within 8w of randomization
3. Evidence ofinﬂammation by two measurements
of ALT42NL within 8w of randomization
1. Antiviral or immunosuppressive therapy within 6m
2. HIV, hepatitis C or D
3. Advanced liver disease or carcinoma
4. Serious medical or psychiatric illness, or uncontrolled thyroid
disease
5. Substance abuse within 2y
6. Pregnancy or inadequate contraception
7. Leucocytes o3000/mm
3, neutrophils o1800/mm
3,o r
platelets o100000/mm
3
ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; INF, interferon; m, months; NEG, HBeAg negative; NL, upper
limit of normal; POS, HBeAg positive; w, weeks; y, years.
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tively, n=1, OR=0.23, 95% CI (0.02–3.3), P=0.16],
PEG group [9.6 vs. 10.3%, respectively, n=1,
OR=0.9, 95% CI (0.3–3.1), P=0.9] and overall [6.0
vs. 9.6%, respectively, n=2, OR=0.6, 95% CI
(0.2–1.9), P=0.55].
All-cause and liver-related mortality
There were no reported deaths of any aetiology for
either group (0% for both).
Safety
No signiﬁcant differences in safety rates were
observed between patients given combination and
monotherapy in the CON group [1.6 vs. 0.9%,
OR=1.7, 95% CI (0.3–9.0), P=0.55, n=6], PEG
group [6.0 vs. 4.2%, OR=1.7, 95% CI (0.9–3.2),
P=0.12, n=2] and overall [4.1 vs. 2.7.%, OR=1.7,
95% CI (0.9–3.1), P=0.10]. Heterogeneity was as-
sessed and not found to be a concern (Q=0.001,
P=0.98).
Group by
Interferon Type
Study name Events/Total Odds ratio and 95% CI
Com Mono
5 3 / 0 1 3 3 / 6 2 Ayaz 2006 N O C
0 3 / 1 1 0 6 / 1 4 Song* 2004 N O C
0 3 / 2 1 2 3 / 0 2 Deng 2003 N O C
6 1 / 3 3 3 / 5 1 Yalcin 2002 N O C
0 5 / 1 2 0 5 / 5 2 Cindoruk 2002 N O C
1 6 1 / 7 5 8 0 2 / 7 2 1 N O C
1 7 2 / 9 3 1 7 2 / 7 3 Lau 2005 G E P
6 3 1 / 9 0 3 1 / 2 1 Janssen 2005 G E P
7 0 4 / 8 4 1 0 4 / 9 4 PEG
8 6 5 / 5 0 1 9 0 6 / 6 7 1 Overall
0.1 0.2 0.5 1 2 5 10
Favours Mono Favours Com
Sustained Virological response
Fig. 1. Sustained virological response. CON, conventional interferon monotherapy vs. its combination with lamivudine; PEG,
pegylated interferon monotherapy vs. its combination with lamivudine. Concurrent and sequential administration.
Com Mono
5 3 / 9 3 3 / 3 1 N O C
0 3 / 6 1 2 3 / 4 2 N O C
6 1 / 3 3 3 / 6 1 N O C
0 5 / 4 2 0 5 / 2 3 N O C
9 6 / 6 1 5 7 / 8 1 N O C
0 0 2 / 8 6 3 2 2 / 3 0 1 N O C
1 7 2 / 1 1 1 1 7 2 / 6 0 1 G E P
6 3 1 / 4 4 0 3 1 / 6 4 G E P
7 0 4 / 5 5 1 1 0 4 / 2 5 1 G E P
7 0 6 / 3 2 2 4 2 6 / 5 5 2 Overall
0.1 0.2 0.5 1 2 5 10
Sustained Biochemical response
Group by
Interferon Type
Study name Events/Total Odds ratio and 95% CI
Ayaz 2006
Deng 2003
Yalcin 2002
Cindoruk 2002
Schalm 2000
Lau 2005
Janssen 2005
Favours Mono Favours Com
Fig. 2. Sustained biochemical response. CON, conventional interferon monotherapy vs. its combination with lamivudine; PEG,
pegylated interferon monotherapy vs. its combination with lamivudine.
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Greater YMDD mutation emergence rates were ob-
served for patients given combination as compared
with monotherapy in the PEG group [4.0 vs. 0%,
OR=18.1, 95% CI (2.4–136.6), P=0.005, n=2] and
overall [4.5 vs. 0%, OR=14.8, 95% CI (2.8–77.6),
P=0.001], although not in the CON group [5.9 vs.
0%, OR=9.9, 95% CI (0.5–177.1), P=0.12, n=1].
Heterogeneity was assessed and not found to be a
concern (Q=0.11, P=0.74).
Conventional interferon combination therapy vs.
pegylated interferon monotherapy
Excluding virological response [61.1 vs. 11.8%,
OR=11.7, 95% CI (7.8–17.6), Po0.0001], no signif-
icant differences in rates of biochemical response [46.2
vs. 38.1%, OR=1.4, 95% CI (1.0–1.9), P=0.052],
HBeAg clearance [33.5 vs. 34.9%, OR=0.9, 95% CI
(0.6–1.4), P=0.77] or seroconversion [30.0 vs. 31.4%,
OR=0.9, 95% CI (0.7–1.3), P=0.73] were observed
between patients given combination therapy in the
Group by
Interferon Type
Study name Events/Total Odds ratio and 95% CI
Com Mono
CON
CON
CON
CON
Song* 2004 22 /60 7/ 30
Deng 2003 16 /32 10/30
Schalm 2000 18 /75 14/69
9 2 1 / 1 3 7 6 1 / 6 5
PEG Lau 2005 77 /271 91/271
PEG Janssen 2005 46 /130 49/136
7 0 4 / 0 4 1 1 0 4 / 23 1 EG P
36 5 / 1 7 1 68 5 / 9 7 1 Overall
0.1 0.2 0.5 1 2 5 10
Sustained HBeAg clearance
Favours Mono Favours Com
Fig. 3. Sustained hepatitis B e antigen (HBeAg) clearance. CON, conventional interferon monotherapy vs. its combination with
lamivudine; PEG, pegylated interferon monotherapy vs. its combination with lamivudine. Concurrent and sequential administration.
Group by
Interferon Type
Study name Events/Total Odds ratio and 95% CI
Com Mono
0 3 / 5 0 6 / 4 1 4 0 0 2 * g n o S ON C
0 3 / 6 2 3 / 8 3 0 0 2 g n e D ON C
6 1 / 3 3 3 / 8 1 2 0 0 2 n i c l a Y ON C
0 5 / 1 1 0 5 / 5 1 2 0 0 2 k u r o d n i C ON C
9 6 / 2 1 5 7 / 0 2 0 0 0 2 m l a h c S ON C
5 9 1 / 7 3 0 5 2 / 5 7 ON C
1 7 2 / 7 8 1 7 2 / 4 7 5 0 0 2 u a L G E P
6 3 1 / 9 3 0 3 1 / 8 3 5 0 0 2 n e s s n a J G E P
7 0 4 / 6 2 1 1 0 4 / 2 1 1 G E P
2 0 6 / 3 6 1 1 5 6 / 7 8 1 Overall
0.1 0.2 0.5 1 2 5 10
Favours Mono Favours Com
Sustained Seroconversion
Fig. 4. Sustained seroconversion. CON, conventional interferon monotherapy vs. its combination with lamivudine; PEG, pegylated
interferon monotherapy vs. its combination with lamivudine. Concurrent and sequential administration.
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group. Signiﬁcantly greater virological response rates
were observed with monotherapy in the CON as
compared with the PEG group [35.4 vs. 11.8%,
OR=4.1, 95% CI (2.6–6.4), Po0.0001].
Discussion
The suboptimal outcomes of current hepatitis B
therapies have prompted the notion of their use in
combination to achieve a synergistic effect and de-
creased mutagenicity (2). Furthermore, it has been
suggested that the enhanced efﬁcacy of the combina-
tion will allow for the dose reduction of its compo-
nents, thus decreasing the risk of potential adverse
effects (2). In our study, we explored this notion in the
subset of HBeAg-positive patients. Our study is the
ﬁrst to examine the combination of interferon and
lamivudine for chronic hepatitis B treatment, pooling
data from all pertinent randomized-controlled trials
into meta-analysis. This analysis will aid in achieving
evidence-based conclusions on the matter, resolving
the controversy in its regard and directing future
investigational efforts.
In our analysis, we found pegylated interferon
monotherapy to be of comparable efﬁcacy to its
combination with lamivudine, providing similar rates
of sustained virological and biochemical responses,
and HBeAg clearance and seroconversion (P=0.66,
0.94, 0.26 and 0.34 respectively). Furthermore, while
the pegylated interferon trials predominantly involved
treatment-naı ¨ve patients, analysis of previously treated
patients within one of those studies yielded similar
outcomes (24). In contrast, the addition of lamivudine
to conventional interferon resulted in superior sus-
tained virological, biochemical and seroconversion
rates (Po0.001, P=0.007, 0.01and 0.09respectively),
similarly observed with sequential and concurrent
administration (20). A similar trend was observed
with HBeAg clearance rates, although the sample size
was insufﬁcient to detect this effect (P=0.09). As with
pegylated interferon, treatment-naı ¨ve patients com-
prised the majority of the studied population and to a
greater extent. Nonetheless, a controlled, nonrando-
mized trial of previously treated patients reported
similar outcomes (25). These outcomes are corrobo-
rated by those of our histological analysis (Po0.001
and P=0.70 for histological improvement in the CON
and PEG groups respectively) and by those of others
(26). Importantly, our analysis provides an explana-
tion to the discordance between the combinations’
effectiveness with conventional and not with pegylated
interferon, with lamivudine-induced mutagenicity
suppressed with the former, while not with the latter
(P=0.12, and 0.05 respectively).
Accordingly, two possible regimens emerged from
our analysis: pegylated interferon monotherapy, and
conventional interferon and lamivudine combination
therapy. Acomparison between the two found them to
be of comparable efﬁcacy (P40.05), with the excep-
tion of virological response (Po0.001). That said, it is
the authors opinion that this combinations’ favour-
able virological response should not prompt its use as
the regimen of choice, as a greater portion of treat-
ment-naı ¨ve and thus easier to treat patients, com-
prised the CON as compared with the PEG group,
with three CON group studies exclusively examining
this patient population (16, 17, 19). Our hypothesis is
further supported by the superior virological out-
comes of conventional as compared with pegylated
interferon monotherapy (Po0.0001), which is in
conﬂict with current knowledge (27), and is easily
explained by this hypothesis. Accordingly, we suggest
that in comparable populations, pegylated interferon
monotherapy is likely to be similarly or more efﬁca-
cious than lamivudine and conventional interferon
combination therapy. More so, the thrice-weekly in-
jection therapy required with conventional interferon
poses a risk of low-patient compliance rates (1–3, 28),
with the risk further exacerbated by the addition of a
second agent. The weekly administration of pegylated
interferon monotherapy is likely to alleviate this con-
cern, while carrying similar economic costs (29).
Consequently, we conclude that pegylated interferon
monotherapy is likely to be the treatment of choice for
HBeAg-positive chronic hepatitis B, with this conclu-
sion being supported by others (27). That said, when
conventional interferon therapy is considered, parti-
cularly in highly compliant patients, its combination
with lamivudine should be entertained.
Similarly, studies examining the HBeAg-negative
hepatitis B population did not ﬁnd the addition of
lamivudine to pegylated (30), or conventional (31),
interferon to be advantageous. In addition, while the
superiority of the combination over lamivudine
monotherapy was suggested in previous studies, this
effect is likely to represent interferon’s greater inherent
efﬁcacy as compared with lamivudine, rather than the
enhanced properties of the combination, as demon-
strated in those very studies (22, 30).
Our study contains several limitations. Firstly, our
use of intention to treat analysis, the methodological
heterogeneity of the included studies, and the hetero-
geneity of their treatment and follow-up protocols,
may have introduced some inaccuracies in our analy-
sis. Notably, while the PEG group comprised large,
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group involved smaller, lower quality ones, thus weak-
ening our conclusions in its regard. Secondly, the
absence of adequate controls precluded the authors
from studying the subsets of treatment-naı ¨ve and
previously treated populations. Those concerns, how-
ever, were alleviated by the low patient lost for follow-
up rates, the lack of statistically signiﬁcant heteroge-
neity across studies, the beneﬁcial effects of the com-
bination with conventional interferon across the
measured indicators and the agreement between our
conclusions and those of other studies.
While the focus of our study was lamivudine and
interferon combination therapy, a plethora of other
combinations have been explored as well. Among
those studied were combinations of interferon and
various antiviral agents (32, 33), interleukin-12 (34)
and prednisone (35). All yielded disappointing results.
Additionally, studies investigating various antiviral
combinations resulted in conﬂicting outcomes
(36–40). Those results indicate the need for further
study, as the goal of a safe and efﬁcacious therapy is yet
to be attained.
Conclusion
Pegylated interferon-a monotherapy is the treatment
of choice for HBeAg-positive chronic hepatitis B, with
no added beneﬁt with lamivudine addition. However,
when conventional interferon therapy is considered,
its combination with lamivudine should be enter-
tained.
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